No significant differences in clinicopathological characteristics were observed in our Chinese cohort between BARD1 and BRCA1 mutation carriers, except that carriers of the BRCA1 mutation had a higher incidence of bilateral breast cancer. This evidence concerns the gene BRCA1 and breast cancer.